French start-ups Pasqal and Qubit Pharmaceuticals are among the 12 selected performers for the Quantum for Bio programme in consortium with the Unitary Fund. Together with the Unitary Fund, Pasqal and Qubit will receive $4.5 million of the total $40 million awarded through the various milestones… Read More
Biomia, the first company spun out from BioInnovation Institute’s Bio Studio programme, has secured $3 million in pre-seed financing from an international syndicate of investors. Biomia says it plans to use the investment to accelerate its development of plant-inspired natural and new-to-nature halogenated small molecule drug… Read More
The BioInnovation Institute (BII) has welcomed three new drug discovery start-ups into its Venture Lab acceleration programme as part of its latest cohort of eight companies. The 12-month Venture Lab programme is designed to support start-up companies with business acceleration, scientific and team development, and provides… Read More
Listen to this article on the DDW Podcast: DDW’s Diana Spencer speaks to Alok Javali, CSO of dawn-bio, a new addition to BioInnovation Institute’s (BII) Venture Lab acceleration programme, about the lack of innovation in women’s reproductive health and the company’s plans to fill the… Read More
SMi Systems has disclosed a £6m ($7.6m) seed funding round to develop and prove the utility of its multi-omic platform for in vitro diagnosis and biomedical research. SMi hopes the technology will significantly accelerate the discovery of new therapeutics by biopharma companies and research institutions. Read More
Vesalius Biocapital, a life sciences venture capital investor, has closed its fourth fund, Vesalius Biocapital IV, securing over €95 million of commitments. The company plans to invest in first and best-in-class European life science companies in drug development and digital health. The goal is to build… Read More
It’s not easy being the new kid on the block. DDW’s Diana Spencer speaks to the CEOs of two drug discovery start-ups to find out how they have overcome the challenges of launching a new company in a competitive market. It’s a challenging time to launch… Read More
Anoat Therapeutics, a preclinical stage biotechnology company specialised in Cystic Fibrosis (CF), has raised €2m ($2.17m) in seed funding from AdBio partners, a venture capital company specialised in seed investments in life sciences startups. This investment from the AFB FII fund stems from the AdBio-Inserm Transfert partnership… Read More
Danish start-up InProTher has raised €6 million seed funding from private investors, with participation from the European Innovation Council (EIC) Fund. The financing will enable InProTher to advance its lead drug candidate, IPT001, a first-in-class immunotherapy against solid tumours, into clinical development. Incubated at… Read More
New South African company NewBiologix has launched with the aim of developing a proprietary and breakthrough platform for the advanced engineering of cell lines used to manufacture gene and cell therapies. The company’s DNA-based platform is being developed to address manufacturing challenges associated with the production… Read More
AI drug discovery company MultiOmic Health has closed a £5 million ($6.2 million) seed funding extension round to build a precision therapeutics discovery platform for metabolic syndrome-related medical conditions. The round was led by London-based Hoxton Ventures, with participation from Ada Ventures, MMC Ventures and Verve… Read More
Listen to this article on the DDW Podcast: DDW takes a look at some key global activity taking place around the world for drug discovery and life sciences start-ups. UK Budget a ‘shot in the arm’ for oncology start-ups Before the UK announced… Read More
BioInnovation Institute Foundation (BII) and Ferring Pharmaceuticals have expanded their collaboration with the objective to accelerate world-class life science innovation within women’s health. New activities will include supporting BII to source and potentially fund and incubate early-stage start-ups and projects within the field of reproductive medicine. Read More
Five drug discovery companies have entered the BioInnovation Institute’s (BII) Venture Lab acceleration programme for early-stage companies as part of a cohort of ten new members. The 12-month Venture Lab programme is designed to support start-up companies with business acceleration, scientific, and team development, and provides a… Read More
Five Alarm Bio (FAB) has completed a seed investment round, raising over £500K ($605K). The funding will drive proprietary research into novel compounds that extend healthy lifespan of cells and tissues, with therapeutic potential across a broad range of age-related diseases. Investors include Cambridge Angels, Meltwind, o2h Ventures, and SyndicateRoom,… Read More
Aera Therapeutics has launched with a vision to “unlock the potential of genetic medicines across a wide range of modalities and therapeutic areas”. The company’s delivery platform is based on research conducted in the laboratory of scientific founder Feng Zhang and aims to address the limitations of… Read More
